Diasorin SpA (EUR)
DIA
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | - |
| Day Range | 109.60 | 113.40 |
| 52-Wk Range | 82.90 | 125.00 |
| Last Close | 116.30 |
| Mkt Cap (m) | 6,364.24 |
| Dividend yield | 0.77% |
| ISIN | IT0003492391 |
| Volume | 285,957 |
| Exchange Venue | MIL |
Company Profile
Diasorin SpA is engaged in the development, manufacture and distribution ofimmunodiagnostics and molecular diagnostics tests.
Key Information
| Price/Earning | 38.38 |
| Price/Book | 7.85 |
| Price/Sales | 9.09 |
| P/CF | 25.71 |
| Rev Growth (3 year avg) | - |
| EPS Growth (3 year avg) | - |
| Operating Margin % | - |
| Net Margin % | - |
| Return on Equity | - |
| Debt/Equity | - |
Documents
Annual Report
| en 31/12/2017 |
Financials
Income Statement
| EUR | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Revenue (m) | 444 | 499 | 569 | 637 | 669 | - |
| Operating Income (m) | 132 | 156 | 178 | 198 | 210 | - |
| Net Income (m) | 84 | 100 | 112 | 140 | 158 | - |
| Basic EPS | 1.55 | 1.83 | 2.05 | 2.54 | 2.85 | - |
| Avg. Diluted Shares Outstanding (m) | 54 | 55 | 55 | 55 | 56 | - |
Balance Sheet
| EUR | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Current Assets (m) | 391 | 494 | 395 | 482 | 415 | - |
| Non Current Assets (m) | 215 | 214 | 473 | 460 | 491 | - |
| Total Assets (m) | 606 | 708 | 869 | 946 | 906 | - |
| Current Liabilities (m) | 82 | 82 | 132 | 141 | 138 | - |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | 483 | 587 | 663 | 741 | 705 | - |
Cash Flows
| EUR | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Operating Cash Flows (m) | 120 | 138 | 166 | 167 | 210 | - |
| Capital Expenditure (m) | -31 | -32 | -37 | -42 | -53 | - |
Figures are quoted in EUR unless stated otherwise
-5.70 (-4.90%)
€
110.60
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.